Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAME-01: Metronomic Paclitaxel, Doxorubicin, and Cyclophosphamide in HER2-Negative Breast Cancer
NCT01329627Phase 2Terminated
- Sponsor
- Instituto do Câncer do Estado de São Paulo
- Start
- Aug 2010
- Primary completion
- Aug 2011
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel oral solution, doxorubicin, cyclophosphamide in breast cancer, sponsored by Instituto do Câncer do Estado de São Paulo. Started Aug 2010; status: terminated.
02
Drugs
paclitaxel oral solutiondoxorubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01329627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01329627.